US 2014 prescription drug spend rose 12.6% on higher expenditure for new hepatitis C treatments - Report
A US government survey has revealed American spending on prescription drug jumped 12.6% in 2014 to $305.1 billion, compared with 2.5% a year ago based on increased spending on new hepatitis C treatments and drugs for cancer and multiple sclerosis.
The report by the US Centers for Medicare and Medicaid Services (CMS) showed the spending spiked primarily due to new hepatitis C treatments like Gilead Sciences' (Nasdaq: GILD) Sovaldi (sofosbuvir). However, the growth in prescription drug spending is expected to slow down in 2015 based on expectations of a price cut for expensive specialty treatments for hepatitis C. On the other hand, spending on prescription drugs is forecast to increase to $328.4 billion this year, and surge to $385.1 billion and $564.3 billion in 2018 and 2024, respectively.
Pricing pressure to lower costs going ahead
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze